The U.S. Food and Drug Administration is warning that certain half-shell oysters that are frozen and raw harvested in South ...

Vaxart Inc., in collaboration with researchers from multiple academic institutions, evaluated the VXA-G1.1-NN vaccine against ...

Vaxart's oral norovirus vaccine shows promise in mid-stage trials, reducing infections by 30%. Read more here.

An oral vaccine reduced infection risk in a trial where people were deliberately exposed to high doses of norovirus, and ...

Vaxart Inc (VXRT) reports significant revenue growth and clinical advancements, despite facing operational hurdles and NASDAQ ...

Actively screening for the 10,000 participant portion of COVID-19 Phase 2b trial; Dosing expected to begin in second quarter of 2025 Completed enrollment of Phase 1 clinical trial evaluating Company’s ...

April 30, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it completed enrollment of its Phase 1 clinical trial evaluating its second-generation oral norovirus vaccine ...

Topline data is expected in mid-2025, marking a key milestone in the development of a needle-free, shelf-stable pill vaccine to address norovirus, a leading global cause of acute gastroenteritis.

It may not be the mythical fountain of youth, but the strength of the body's immune system, or immune resilience, could hold ...

HilleVax reports Q1 2025 financials: $159.5 million in assets, reduced losses, and ongoing vaccine development for norovirus. HilleVax, Inc. announced its financial results for the first quarter ...